Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab Adjuvant Therapy in Node-positive Esophageal Squamous Cell Carcinoma
NCT06190639Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Zhejiang Cancer Hospital. Started Oct 2023; status: recruiting.
02
Drugs
sintilimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT06190639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06190639.